Compounds > fosmidomycin monosodium salt
Page last updated: 2024-12-10

fosmidomycin monosodium salt

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5141362
CHEMBL ID2164257
SCHEMBL ID4432387
MeSH IDM0315878

Synonyms (23)

Synonym
66508-37-0
antibiotic fr 31564
fr 31564
phosphonic acid, (3-(formylhydroxyamino)propyl)-, monosodium salt
(3-(formylhydroxyamino)propyl)phosphonic acid monosodium salt
iyi1ew66cx ,
unii-iyi1ew66cx
fosmidomycin sodium
CHEMBL2164257
FT-0613838
fosmidomycin sodium salt
fosmidomycin sodium [jan]
fosmidomycin monosodium salt [mi]
fosmidomycin monosodium salt
SCHEMBL4432387
DTXSID10216711
AKOS030254266
HY-112853
CS-0067087
Q27280957
66508-37-0 (sodium)
sodium hydrogen [3-(n-hydroxyformamido)propyl]phosphonate
sodium;3-[formyl(hydroxy)amino]propyl-hydroxyphosphinate
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (4)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12IC50 (µMol)0.22000.02000.74213.5000AID1166106
1-deoxy-D-xylulose 5-phosphate reductoisomeraseMycobacterium tuberculosis H37RvIC50 (µMol)0.23000.08000.41892.3900AID1608493
1-deoxy-D-xylulose 5-phosphate reductoisomerase, apicoplasticPlasmodium falciparum 3D7IC50 (µMol)0.08600.03400.08600.1600AID1386716; AID1386718; AID1608491
1-deoxy-D-xylulose 5-phosphate reductoisomerase Escherichia coliIC50 (µMol)0.22000.22000.32900.4380AID1608492
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (3)

Processvia Protein(s)Taxonomy
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isoprenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
isopentenyl diphosphate biosynthetic process, methylerythritol 4-phosphate pathway involved in terpenoid biosynthetic process1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (6)

Processvia Protein(s)Taxonomy
oxidoreductase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
manganese ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
1-deoxy-D-xylulose-5-phosphate reductoisomerase activity1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
identical protein binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
metal ion binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
NADPH binding1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
Dxr protein complex1-deoxy-D-xylulose 5-phosphate reductoisomeraseEscherichia coli K-12
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (28)

Assay IDTitleYearJournalArticle
AID1524922Antitubercular activity against Mycobacterium tuberculosis H37Rv reduction in bacterial multiplication incubated for 7 days by luminometric assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1524899Oral bioavailability in human2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Phosphonodiamidate prodrugs of N-alkoxy analogs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1653791Substrate activity at human mARC1 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID1608496Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 24 hrs by neutral red assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID698702Antiplasmodial activity against chloroquine-sensitive Plasmodium falciparum 3D7 incubated for 3 days by HRP2 detection based ELISA method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
α-Substituted β-oxa isosteres of fosmidomycin: synthesis and biological evaluation.
AID1653796Substrate activity at human mARC2 expressed in Escherichia coli assessed as turnover rates at 3 mM pre-incubated for 3 mins followed by NADH addition and measured after 15 mins by UV-Visible spectroscopy based NADH assay2020Journal of medicinal chemistry, 06-25, Volume: 63, Issue:12
Drug Metabolism by the Mitochondrial Amidoxime Reducing Component (mARC): Rapid Assay and Identification of New Substrates.
AID698703Antiplasmodial activity against chloroquine-resistant Plasmodium falciparum Dd2 incubated for 3 days by HRP2 detection based ELISA method2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
α-Substituted β-oxa isosteres of fosmidomycin: synthesis and biological evaluation.
AID1524920Antiplasmodial activity against Plasmodium falciparum K1 infected in human erythrocytes assessed as reduction in parasite multiplication incubated for 72 hrs by Malstat method2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1386718Inhibition of Plasmodium falciparum DXR assessed as reduction in NADPH oxidation in presence of DOXP by UV-visible spectrophotometry2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.
AID1422837Cytotoxicity against human MRC5 cells after 24 hrs by resazurin assay2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents.
AID1386716Inhibition of Plasmodium falciparum DXR2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.
AID1524918Oral bioavailability in healthy human at 500 mg2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1524900Half life in human at 500 mg, po2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
Phosphonodiamidate prodrugs of N-alkoxy analogs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1608492Inhibition of recombinant Escherichia coli IspC expressed in Escherichia coli M15 using 1-deoxy-D-xylulose 5-phosphate as substrate by photometric assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID1386721Growth inhibition of Plasmodium falciparum 3D7 asynchronous cultures by PicoGreen dye based assay2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.
AID1608491Inhibition of recombinant Plasmodium falciparum IspC expressed in Escherichia coli using 1-deoxy-D-xylulose 5-phosphate as substrate by photometric assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID1422842Half life in patient with malaria2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents.
AID1386717Growth inhibition of Plasmodium falciparum2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.
AID1166106Inhibition of Escherichia coli M15 recombinant IspC using 1-deoxy-D-xylulose 5-phosphate as substrate by photometric analysis2014Journal of medicinal chemistry, Nov-13, Volume: 57, Issue:21
Binding modes of reverse fosmidomycin analogs toward the antimalarial target IspC.
AID1422841Oral bioavailability in patient with malaria2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents.
AID1422836Antimicrobial activity against Mycobacterium tuberculosis H37Ra ATCC 25177 after 7 days by luminometric method2018ACS medicinal chemistry letters, Oct-11, Volume: 9, Issue:10
Acyloxybenzyl and Alkoxyalkyl Prodrugs of a Fosmidomycin Surrogate as Antimalarial and Antitubercular Agents.
AID1608495Antimalarial activity against asexual blood stages of Plasmodium falciparum Dd2 infected in human erythrocytes incubated for 3 days by ELISA2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID698704Inhibition of recombinant Plasmodium falciparum recombinant IspC using [3,4,5-13C3]1-Deoxy-D-xylulose 5-phosphate substrate by photometric assay2012Journal of medicinal chemistry, Jul-26, Volume: 55, Issue:14
α-Substituted β-oxa isosteres of fosmidomycin: synthesis and biological evaluation.
AID1386720Inhibition of Plasmodium falciparum DXR assessed as reduction in NADPH oxidation at 100 uM in presence of DOXP by UV-visible spectrophotometry2018Journal of medicinal chemistry, 10-11, Volume: 61, Issue:19
MEPicides: α,β-Unsaturated Fosmidomycin Analogues as DXR Inhibitors against Malaria.
AID1608493Inhibition of recombinant Mycobacterium tuberculosis IspC expressed in Escherichia coli M15 using 1-deoxy-D-xylulose 5-phosphate as substrate by photometric assay2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
AID1524923Cytotoxicity in human MRC5 cells assessed as reduction in cell viability incubated for 24 hrs by resazurin-based cytotoxicity assay2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1524919Half life in healthy human at 500 mg, po2019Bioorganic & medicinal chemistry letters, 05-15, Volume: 29, Issue:10
Double prodrugs of a fosmidomycin surrogate as antimalarial and antitubercular agents.
AID1608494Antimalarial activity against asexual blood stages of Plasmodium falciparum 3D7 infected in human erythrocytes incubated for 3 days by ELISA2019European journal of medicinal chemistry, Nov-01, Volume: 181Novel reverse thia-analogs of fosmidomycin: Synthesis and antiplasmodial activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (87.50)24.3611
2020's1 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.51 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		2.2110ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
chloroquine
Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.		2.8930aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound		anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug
hydroxyurea
[no description available]		2.2510one-carbon compound;
ureas		antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent
isoniazid
Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).		2.6120carbohydrazideantitubercular agent;
drug allergen
leflunomide
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.		2.2510(trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide		antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor
zonisamide
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.		2.25101,2-benzoxazoles;
sulfonamide		anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker
6-hydroxyadenosine
[no description available]		2.2510
amitriptyline n-oxide
[no description available]		2.2510organic tricyclic compound
zidovudine
Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.		2.2510azide;
pyrimidine 2',3'-dideoxyribonucleoside		antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor
4-(n-methyl-n-nitrosamino)-1-(3-pyridyl)-1-butanone
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone: structure; from tobacco smoke		2.2510nitrosamine;
pyridines
zileuton
[no description available]		2.25101-benzothiophenes;
ureas		anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug
ziprasidone
ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.		2.25101,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines		antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist
artemisinin
(+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.		2.1710organic peroxide;
sesquiterpene lactone		antimalarial;
plant metabolite
nicotinamide n-oxide
[no description available]		2.2510pyridines
3-(n-acetyl-n-hydroxy)aminopropylphosphonic acid
3-(N-acetyl-N-hydroxy)aminopropylphosphonic acid: from Streptomyces rubellomurinus sp. nov.; interferes with bacterial cell wall synthesis; structure in first source		2.1710phosphonoacetic acid
n(4)-hydroxycytidine
N(4)-hydroxycytidine : A nucleoside analogue that is cytidine which carries a hydroxy group at the N(4)-positon. It has broad-spectrum antiviral activity against influenza, SARS-CoV , SARS-CoV-2 and MERS-CoV.		2.2510ketoxime;
nucleoside analogue		anticoronaviral agent;
antiviral agent;
drug metabolite;
human xenobiotic metabolite
tamoxifen
[no description available]		2.6120stilbenoid;
tertiary amino compound		angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator
benzamidoxime
benzamidoxime: structure given in first source. benzamidoxime : A member of the class of amidoximes obtained by formal condensation of the carbonyl group of benzamide with hydroxylamine.		2.2510amidoximebacterial metabolite;
genotoxin;
mammalian metabolite
guanoxabenz
[no description available]		2.2510
upamostat
[no description available]		2.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Plasmodium falciparum Malaria
[description not available]		02.1710
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.1710